(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.82%) $83.16
(-1.16%) $1.619
(-0.45%) $2 336.70
(0.87%) $27.49
(0.55%) $927.20
(-0.16%) $0.933
(-0.15%) $11.01
(-0.24%) $0.798
(0.00%) $92.17
1.83% € 94.60
Live Chart Being Loaded With Signals
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 49 622.00 |
Średni wolumen | 20 205.00 |
Kapitalizacja rynkowa | 4.21B |
EPS | €0 ( 2024-03-14 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | 47.78 |
ATR14 | €0.139 (0.15%) |
Wolumen Korelacja
Financiere de Tubize SA Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Financiere de Tubize SA Korelacja - Waluta/Towar
Financiere de Tubize SA Finanse
Annual | 2023 |
Przychody: | €0 |
Zysk brutto: | €-2.03M (0.00 %) |
EPS: | €1.980 |
FY | 2023 |
Przychody: | €0 |
Zysk brutto: | €-2.03M (0.00 %) |
EPS: | €1.980 |
FY | 2022 |
Przychody: | €8 151.00 |
Zysk brutto: | €-1.82M (-22 327.55 %) |
EPS: | €3.91 |
FY | 2021 |
Przychody: | €0.00 |
Zysk brutto: | €0.00 (0.00 %) |
EPS: | €8.54 |
Financial Reports:
No articles found.
Financiere de Tubize SA
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej